Beginning Cash: The amount of cash reported by the company on its previous statement.
Qualigen Therapeutics, Inc. (QLGN) had Beginning Cash of $7.04M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-13.42M |
|
-- |
|
-- |
|
$11.30M |
|
$-11.30M |
|
$-1.17M |
|
$-12.48M |
|
$-12.46M |
|
$-12.47M |
|
$-12.47M |
|
$-13.76M |
|
$-12.45M |
|
$-11.30M |
|
$-9.83M |
|
0.10M |
|
0.10M |
|
$-132.25 |
|
$-132.25 |
|
| Balance Sheet Financials | |
$1.17M |
|
-- |
|
$0.87M |
|
$2.03M |
|
$4.14M |
|
-- |
|
-- |
|
$4.14M |
|
$-2.10M |
|
$-2.10M |
|
$-2.10M |
|
0.11M |
|
| Cash Flow Statement Financials | |
$-10.30M |
|
$4.22M |
|
$-0.55M |
|
|
Beginning Cash |
$7.04M |
$0.40M |
|
$-6.64M |
|
$1.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.28 |
|
-- |
|
-- |
|
-- |
|
-0.62 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.30M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
593.04% |
|
593.04% |
|
-613.55% |
|
593.04% |
|
$-19.62 |
|
$-101.57 |
|
$-101.57 |
|